Scientific Advisors

Scientific Advisors

We have assembled a leading team of advisors with deep domain expertise.


Inflammatory Bowel Disease

Sean Colgan, PhD
Dr. Colgan is the Director of the Mucosal Inflammation Program and Vice Chairman of the Department of Medicine at the University of Colorado. Dr. Colgan’s research focuses on the identification Read More
Sean Colgan, PhD

Dr. Colgan is the Director of the Mucosal Inflammation Program and Vice Chairman of the Department of Medicine at the University of Colorado. Dr. Colgan’s research focuses on the identification of novel anti-inflammatory molecules associated with mucosal inflammation. He is one of world’s leading experts on Specialized Proresolving Mediators (SPMs), having served on the faculty at Harvard Medical School in the Center for Experimental Therapeutics under the tutelage of Dr. Charles Serhan, who created the modern field of resolution biology. Dr. Colgan has published more than 170 original papers, served as a Section Editor for the Journal of Immunology, and is a standing member of the GMPB study section at the NIH. He is the previous chairman of the Research Fellowship Award study section for the CCFA and presently serves as the chairman of the CCFA Senior Research Award study section.

Asma Nusrat, MD
Dr. Asma Nusrat is a leading research clinician in the field of epithelial wound healing in the context of inflammatory bowel disease (IBD). Asma trained and became certified in Anatomic Read More
Asma Nusrat, MD

Dr. Asma Nusrat is a leading research clinician in the field of epithelial wound healing in the context of inflammatory bowel disease (IBD). Asma trained and became certified in Anatomic Pathology at the Brigham and Women’s Hospital (BWH)/Harvard Medical School after which she completed a fellowship in Gastrointestinal and Hepatobiliary pathology, as well as a postdoctoral research fellowship in epithelial cell biology at the same institution. While at BWH, she began investigating fundamental mechanisms of epithelial barrier regulation and wound repair. During this time, she was successful in obtaining NIH funding, advancing from NRSA to K08 grants and rose to the rank of Assistant Professor. She left BWH to join the faculty at Emory University to continue developing a highly successful research program centered on mucosal pathobiology in the gut, training fellows and graduate students and performing clinical service as a gastrointestinal pathologist. At Emory, Asma was highly successful in obtaining multiple NIH grants while remaining clinically active in gastrointestinal surgical pathology. She rapidly rose through the ranks and was promoted to professor with tenure in 2007. In 2015, Asma left Emory to join the faculty in the department of pathology at the University of Michigan where she was appointed as the Aldred Scott Warthin Professor and Director of Experimental Pathology.

In her lab, Asma continues a long standing quest to elucidate the pathologic mechanisms of chronic inflammatory diseases of the gut and mucosal wound repair. She has published more than 150 papers, many in high profile journals, regularly speaks at national and international symposia related to her field, and has served as an Associate Editor for leading journals in the field for over a decade. In addition to her robust research program, Asma remains clinically active as a practicing Gastrointestinal and Liver Pathologist while enjoying mentoring and teaching graduate and medical students, residents, postdoctoral fellows and junior faculty.

Stephen Hanauer, MD
Dr. Hanauer is an internationally recognized expert on the treatment of inflammatory bowel disease. He currently serves as the medical director of the Digestive Disease Center at Northwestern University Feinberg Read More
Stephen Hanauer, MD

Dr. Hanauer is an internationally recognized expert on the treatment of inflammatory bowel disease. He currently serves as the medical director of the Digestive Disease Center at Northwestern University Feinberg School of Medicine and as the Clifford Joseph Barborka Professor of Medicine. After earning his medical degree from the University of Illinois, Dr. Hanauer completed his internship and residency in internal medicine followed by a fellowship in gastroenterology at the University of Chicago. There Dr. Hanauer was mentored by one of the great clinicians in American gastroenterology, the legendary Dr. Joseph B. Kirsner. Dr. Hanauer held a Professorship in Medicine at Chicago named for Dr. Kirsner.

As Chairman of the Gastrointestinal Drugs Advisory Committee at the US Food and Drug Administration, Dr. Hanauer authored the FDA’s “Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease”. From 2014-2015, he served as president of the American College of Gastroenterology (ACG), where he has been a member of the ACG Board of Trustees since 2006, an officer of the ACG since 2010 and a contributing committee member since 1989. He has represented the ACG at the FDA related to development of end-points for IBD in a series of “GREAT” meetings. He edited Nature Reviews Gastroenterology & Hepatology and chaired the ACG Finance Committee from 2011 to 2012. Dr. Hanauer has also held leadership positions in the American Gastroenterological Association (AGA) as chair of the Sections on Infection, Immunology and Inflammatory Bowel Disease as well as Clinical Practice, and served on the AGA Governing Board as a Counselor for Clinical Research. Internationally, he is a member of the European Crohn’s and Colitis Organization (ECCO) and is a former chairman of the International Organization for IBD (IOIBD).

Dr. Hanauer was awarded the AGA Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology in 2001 and the AGA Janssen Award for Clinical Excellence in GI in 2004. He is currently an Associate Editor for Clinical Gastroenterology and Hepatology. In addition, Dr. Hanauer has worked with the American Board of Internal Medicine serving on the Gastroenterology sub-specialty. He has also held leadership positions within the Crohn’s & Colitis Foundation of American and in 2011 received CCFA’s Scientific Achievement Award for Clinical Research. Over the course of his career, Hanauer has authored or co-authored hundreds of peer-reviewed journal articles, books, book chapters, monographs, and editorials.

Josh Korzenik, MD
Dr. Joshua R. Korzenik, one of the leading IBD researchers and key opinion leaders in the country, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and Read More
Josh Korzenik, MD

Dr. Joshua R. Korzenik, one of the leading IBD researchers and key opinion leaders in the country, is director of the Brigham & Women’s Hospital Crohn’s and Colitis Center and assistant professor at Harvard Medical School. Dr. Korzenik has been involved in IBD research and care of patients for almost 25 years, with his research focusing on 1) translational research in IBD and 2) investigating environmental influences in IBD, with a focus on their common nexus of the intestinal microbiome. Dr. Korzenik is the author of almost 60 peer-reviewed articles and research papers. He speaks frequently at professional meetings and is an active member of many professional committees. Dr. Korzenik has been the principal investigator of over a dozen research projects, ranging from studies of diet and probiotics to international comparisons of IBD. Dr. Korzenik earned his bachelor’s degree from Harvard College in 1980 and his medical degree from Albert Einstein College of Medicine in the Bronx, New York, in 1987. He was a resident at Harvard-affiliated Beth Israel Deaconess Hospital in Boston from 1987 to 1990 and fellow in gastroenterology and clinical epidemiology at Yale University School of Medicine Hospital from 1991 to 1994. He is a longstanding member of the medical advisory committee for the New England chapter of Crohn’s and Colitis Foundation of America.

Florian Rieder, MD
Dr. Rieder is an investigator at the Department of Pathobiology and an Associate Staff at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus Read More
Florian Rieder, MD

Dr. Rieder is an investigator at the Department of Pathobiology and an Associate Staff at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with inflammatory bowel diseases (IBD) with a special emphasis on the field of pathogenesis, prediction and therapy of IBD.

Dr. Rieder has published more than 60 articles and book chapters and has been recognized for his expertise and he serves on multiple committees, speakers’ panels, steering committees and editorial boards. He is a member of the European Crohn’s and Colitis Organization (ECCO), the German Gastroenterology Association, the American Gastroenterology Association, the America Physiological Society, the American College of Physicians, and the Crohn’s and Colitis Foundation. He is the associate editor of Clinical and Translational Gastroenterology, section editor of Annals of Gastroenterology, on the editorial boards of the Journal of Crohn’s and ColitisInflammatory Bowel DiseasesBMC GastroenterologyAmerican Journal of Physiology: Gastrointestinal and Liver Physiology and Gastroenterology and Hepatology Journal. Dr. Rieder is the senior author of the new ECCO guidelines for Ulcerative colitis, the first author of the ECCO consensus on Fibrostenosing IBD and co-author of the new ECCO guidelines in Crohn’s disease.

He received his medical degree from the Ludwig-Maximilians-University Medical School in Germany. He underwent training in Internal Medicine / Gastroenterology at the Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, Germany and a residency in Internal Medicine and fellowship in Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic in Cleveland, Ohio. Dr. Rieder has performed research fellowships at Harvard Medical School and the Cleveland Clinic.

Bill Sandborn, MD
William Sandborn, MD, is a board-certified gastroenterologist who is one of the world’s top experts in the management of ulcerative colitis and Crohns disease. He directs the Inflammatory Bowel Disease Read More
Bill Sandborn, MD

William Sandborn, MD, is a board-certified gastroenterologist who is one of the world’s top experts in the management of ulcerative colitis and Crohns disease. He directs the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health.

In addition, he is chief of the Division of Gastroenterology, vice chair of clinical operations for the Department of Medicine, and a member of the Clinical Practice Oversight (CPO) Board for UC San Diego Health.

A professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators.

With his physician collaborators, he evaluates and develops new diagnostic modalities and medical therapies for inflammatory bowel disease. Dr. Sandborn is internationally recognized for his contributions in the fields of biotechnology therapy, clinical pharmacology, conduct of clinical trials, diagnostic and treatment of pouchitis, epidemiology and natural history, and endoscopic and radiographic imaging techniques.

His clinical trials have been instrumental to developing modern treatments for IBD.

Dr. Sandborn has published nearly 600 articles in prestigious journals, including the New England Journal of Medicine, The Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology.

Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minn.

Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine. He is board-certified in gastroenterology.

Respiratory

Charles Serhan, PhD, DSc
Charles Nicholas Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and also Professor of Oral Medicine, Infection and Immunity at Harvard School Read More
Charles Serhan, PhD, DSc

Charles Nicholas Serhan is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and also Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine; He is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Dr. Serhan’s pioneering studies on the chemistry-medicine interface have resulted in the discovery of the Specialized Pro-resolving Mediators (SPMs), a super-family of biochemical mediators that actively orchestrate the resolution of inflammation and provide the molecular underpinnings for a new era in inflammation resolution pharmacology.

Charles received a BS in biochemistry from Stony Brook University followed by a Doctorate in experimental pathology and medical sciences from New York University School of  Medicine. He was a visiting scientist and post-doctoral fellow at the Karolinska Institutet, Stockholm with Professor Bengt Samuelsson (Nobel Laurate Medicine 82). In 1987, he joined the faculty at Harvard Medical School and received an honorary degree from Harvard University (1996).

He has received several awards including an NIH MERIT award and has delivered > 50 keynote and plenary lectures. Among these recent awards are: the 2008 William Harvey Outstanding Scientist Medal and AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology Bonazinga Award, The American College of Rheumatology Hench (Nobel Laurate) Award Lecture in 2011 presented by the Mayo Clinic Hench Society, and Mérieux 2013 Laureate.
In 2016, he received the IUBMB Lecture Metal and the Ross Prize in Molecular Medicine. Recently, he received the International Eicosanoid Research Foundation’s 2017 Lifetime Achievement Award and the American Society of Investigative Pathology 2018 Rous Whipple Award and the 2018 Gaddum International Prize and Award Lecture from the British Pharmacology Society.

Richard Albert, MD
Dr. Albert is a member of the Department of Medicine Division of Pulmonary Sciences and Critical Care Medicine at University of Colorado School of Medicine and is the department’s Vice Read More
Richard Albert, MD

Dr. Albert is a member of the Department of Medicine Division of Pulmonary Sciences and Critical Care Medicine at University of Colorado School of Medicine and is the department’s Vice Chair for Clinical Affairs. Albert’s decades-long research program has focused on laboratory and clinical studies targeting the pathophysiology and treatment of ARDS, and clinical trials aimed at trying to reduce and treat acute exacerbations of COPD. In ARDS, Dr. Albert has led research on the use of intermittent sighs incorporated into mechanical ventilation based on the idea that stretching the lung causes the type 2 pneumocytes to secrete surfactant. Dr. Albert graduated from the University of Colorado School of Medicine

Bruce Levy, MD
Dr. Bruce Levy is a leading expert on Resolvin pharmacology in pulmonary diseases, and his seminal research on Resolvin E1 in ARDS and asthma models laid the foundation for Thetis’ Read More
Bruce Levy, MD

Dr. Bruce Levy is a leading expert on Resolvin pharmacology in pulmonary diseases, and his seminal research on Resolvin E1 in ARDS and asthma models laid the foundation for Thetis’ TP-317 program. As noted in his letter of support, Dr. Levy has volunteered to serve as the principal investigator leading the clinical investigation of TP-317 in ARDS. He is currently the Division Chief of the Pulmonary and Critical Care Medicine Division at Brigham and Women’s Hospital (BWH) and on faculty at Harvard Medical School. Dr. Levy is board-certified in critical care medicine and pulmonary disease. He has written more than 120 peer-reviewed publications, and currently serves as associate editor of the American Journal of Respiratory and Critical Care Medicine and The New England Journal of Medicine’s clinical problem-solving interactive case series. Dr. Levy received his medical degree from the University of Pennsylvania School of Medicine (now the Perelman School of Medicine), and completed a fellowship in pulmonary and critical care medicine at BWH.

Non-alcoholic Steatohepatitis

Anna Mae Diehl, MD
Dr. Diehl is a leading researcher in the field of nonalcoholic fatty liver disease (NAFLD) with a long standing interest in liver injury and repair. She is currently the Director Read More
Anna Mae Diehl, MD

Dr. Diehl is a leading researcher in the field of nonalcoholic fatty liver disease (NAFLD) with a long standing interest in liver injury and repair. She is currently the Director of the Duke Liver Center and the Florence McAlister Professor of Medicine at the Duke University School of Medicine.

Dr. Diehl has conducted seminal research in many areas, including liver regeneration, the role of cytokines in liver disease, and hepatocellular cancer. In addition, she has conducted the definitive work in understanding the important role of Hedgehog signaling proteins in liver pathobiology, from liver regeneration, to hepatic fibrosis, to activation of stellate cells, growth of progenitor cells, and development of cirrhosis. Dr. Diehl was also one of the first researchers to demonstrate that fatty liver is not a reversible innocuous condition, but a frequent cause of severe liver damage, evolving into non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.

Dr. Diehl has been an active participant in the NIDDK-funded Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), a national consortium comprised of 8 university medical centers selected to generate a national registry for patients with NAFLD and to conduct multicenter treatment trials for this disorder. Diehl has received extensive grant funding from the National Institutes of Health and has authored more than 250 peer-reviewed articles. She is a recipient of numerous awards, including the Leon Schiff Award, the Hans Popper Award, the Sheila Sherlock Award from the British Society of Gastroenterology, and the American Association for the Study of Liver Diseases Distinguished Achievement Award.

She received her M.D. from Georgetown University, followed by residency and a fellowship in gastroenterology at Johns Hopkins University.

Joel Lavine, MD, PhD
Joel E. Lavine, MD, PhD, is tenured Professor of Pediatrics, also in the Institute of Human Nutrition, Division of Gastroenterology, Hepatology and Nutrition at Columbia College of Physicians and Surgeons. Read More
Joel Lavine, MD, PhD

Joel E. Lavine, MD, PhD, is tenured Professor of Pediatrics, also in the Institute of Human Nutrition, Division of Gastroenterology, Hepatology and Nutrition at Columbia College of Physicians and Surgeons. A noted physician-scientist, his research centers around the etiopathogenesis, genetics, natural history, environmental provocation, biomarker/bioimaging development and treatment of particular pediatric liver diseases, with emphasis on fatty liver.

Since 2002, Prof. Lavine has been the sole Pediatric Principal Investigator funded by the NIDDK for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). He is the sole pediatric co-author for the Guidelines for NASH from the American Association for the Study of Liver Diseases (AASLD), as well as the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG). Prof. Lavine has served as the primary author on numerous clinical trials in adult and pediatric NAFLD/NASH, and along with Dr. Vos (primary author), served as corresponding author for the manuscript published in 2020 in Gastroenterology on “Factors to Consider in the Development of Drugs for Pediatric NAFLD”, along with representatives from the FDA, EMA, and numerous industry partners.

He chaired and co-chaired numerous NIH committees, including the NASH CRN Steering Committee, the NASH CRN Database Committee, and the NASH CRN Pediatric Committee. He has Chaired numerous NIH Grant Review Panels, the NIDDK Data and Safety Monitoring Board of the Cholestatic Liver Disease Research and Education Network (ChiLDReN), and TEEN-LABS (Longitudinal Assessment for Bariatric Surgery.

Prof. Lavine earned his doctorate in Molecular Biology in 1980 at the University of California, Santa Barbara, and his Medical Degree from the University of California, San Diego, in 1984. He is board certified in pediatrics and pediatric gastroenterology, where he trained at the University of California, San Francisco. He has been a Division Chief at UC San Diego and Columbia University for 25 years.

Michael Davidson, MD
Dr. Michael Davidson is an experienced pharmaceutical executive and clinician with deep expertise in Omega-3 fatty acids and metabolic disease. He is currently the CEO of New Amsterdam Pharma and Read More
Michael Davidson, MD

Dr. Michael Davidson is an experienced pharmaceutical executive and clinician with deep expertise in Omega-3 fatty acids and metabolic disease. He is currently the CEO of New Amsterdam Pharma and was founder and Chief Medical Officer of Corvidia Therapeutics which sold to Novo Nordisk in July 2020.

Michael was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996.

His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Michael received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.